CHIASMA, INC·4

Feb 26, 9:06 PM ET

Fitzpatrick Mark J. 4

4 · CHIASMA, INC · Filed Feb 26, 2018

Insider Transaction Report

Form 4
Period: 2018-02-23
Fitzpatrick Mark J.
CFO, Treasurer
Transactions
  • Award

    Stock Option (Right to Buy)

    2018-02-23+67,96767,967 total
    Exercise: $1.52Exp: 2028-02-23Common Stock (67,967 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-02-23+194,183194,183 total
    Exercise: $1.52Exp: 2028-02-23Common Stock (194,183 underlying)
Footnotes (2)
  • [F1]The shares of Common Stock underlying the option will vest in quarterly installments over 4 years from the date of grant.
  • [F2]The shares of Common Stock underlying the option will vest as follows: 40% of such award will be earned upon FDA acceptance of a new drug application (NDA) for Mycapssa, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such acceptance; 60% of such award will be earned upon FDA approval of such NDA, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such approval.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION